For richer charts and full features, open SpikePanel on desktop.
Graded daily on value A+, growth B+, profitability C-, momentum D, revisions C. Sector-relative, identical for every user.
Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $CVS are available with SpikePanel Pro.
Key events, in time order
Retail division offers gifts and decor to boost seasonal spending
Management addresses investor questions on separation costs and competitiveness
Analyst sees 13-25% upside to intrinsic value, market weighs execution risk
Q3 2026 adjusted EPS was $2.09, up over 30% from the prior year quarter.
Multiple sources see CVS turnaround driving Q3 acceleration, meaningful long-term upside
Company confirms date; Zacks sees potential for another beat
IRA pricing changes create revenue headwinds, but company maintains profitability through distribution agreements
Baird ups stake 4% to 10,059 shares, adding institutional vote of confidence.
Higher script volumes and improved margins lift segment operating income to $1.48B.
Extends prior flu vaccine event with new COVID-19 vaccine availability, broadening product offering
Company announcement confirms 2026-2027 season vaccines in stores, appointments and walk-ins accepted
Institutional buying signals long-term confidence, adding to recent earnings beat and raised guidance
Health Care Benefits profitability drives EPS up over 40%, FY AOI outlook raised, but medical costs and Caremark risks persist.
Arvest Bank Trust raises stake 2401.7%, Bessemer Group 34.9%, extending institutional accumulation trend
CVS Pharmacy now fills common pet prescriptions nationwide, expanding its service offering.
None yet
None yet
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice